Kantarjian, Hagop

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

Ravandi, F., Gojo, I., Patnaik, M. M., Minden, M. D., Kantarjian, H., Johnson-Levonas, A. O., Fancourt, C., Lam, R., Jones, M. B., Knox, C. D., et al. (2016) · Leukemia Research

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 57

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia

Gong, Z., Medeiros, L. J., Cortes, J. E., Zheng, L., Khoury, J. D., Wang, W., Tang, G., Loghavi, S., Luthra, R., Yang, W., et al. (2017) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 56

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Bidikian, A., Kantarjian, H., Jabbour, E., Short, N. J., Patel, K., Ravandi, F., Sasaki, K., & Issa, G. C. (2022) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 55

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Zhao, Y., Short, N. J., Kantarjian, H. M., Chang, T.-C., Ghate, P. S., Qu, C., Macaron, W., Jain, N., Thakral, B., Phillips, A. H., et al. (2023) · Blood

Acute Lymphoblastic Leukemia researchCAR-T cell therapy research

Cited by 41

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Zhao, Y., Short, N. J., Kantarjian, H. M., Chang, T.-C., Ghate, P. S., Qu, C., Macaron, W., Jain, N., Thakral, B., Phillips, A. H., et al. (2024) · Blood

Acute Lymphoblastic Leukemia researchCAR-T cell therapy research

Cited by 41

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

Cortes, J., Kantarjian, H., Ball, E. D., DiPersio, J., Kolitz, J. E., Fernandez, H. F., Goodman, M., Borthakur, G., Baer, M. R., & Wetzler, M. (2012) · Cancer

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 37

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

Lontos, K., Saliba, R. M., Kanagal-Shamanna, R., Özcan, G., Ramdial, J., Chen, G., Kadia, T., Short, N. J., Daver, N. G., Kantarjian, H., et al. (2025) · Blood Advances

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 35

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial

Jabbour, E., Oehler, V. G., Koller, P. B., Jamy, O., Lomaia, E., Hunter, A. M., Uspenskaya, O., Samarina, S., Mukherjee, S., Cortes, J. E., et al. (2025) · JAMA Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 33

Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor

Bidikian, A., Jabbour, E., Issa, G. C., Short, N. J., Sasaki, K., & Kantarjian, H. (2023) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 32

Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results

Gener-Ricos, G., Haddad, F. G., Sasaki, K., Issa, G. C., Skinner, J., Masarova, L., Borthakur, G., Alvarado, Y., Garcia-Manero, G., Jabbour, E., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 30

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Ottmann, O., Saglio, G., Apperley, J. F., Arthur, C., Bullorsky, E., Charbonnier, A., Dipersio, J. F., Kantarjian, H., Khoury, H. J., Kim, D.-W., et al. (2018) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 30

Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition

Burger, J. A., Landau, D., Hoellenriegel, J., Sougnez, C., Schlesner, M., Ishaque, N., Brors, B., Keating, M. J., Wierda, W. G., Cibulskis, K., et al. (2013) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 29

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 26

The prognostic significance of bone marrow levels of neurofibromatosis‐1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome

Lu, D., Nounou, R., Beran, M., Estey, E., Manshouri, T., Kantarjian, H., Keating, M. J., & Albitar, M. (2003) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 23

The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors

Jabbour, E. J., Sasaki, K., Haddad, F. G., Issa, G. C., Garcia‐Manero, G., Kadia, T. M., Jain, N., Yilmaz, M., DiNardo, C. D., Patel, K. P., et al. (2023) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 22

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

Chihara, D., Masarova, L., Newberry, K. J., Maeng, H., Ravandi, F., Garcia-Manero, G., Ferrajoli, A., Cortes, J., Kantarjian, H., & Verstovsek, S. (2016) · Leukemia Research

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 21

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Han, L., Cavazos, A., Baran, N., Zhang, Q., Kuruvilla, V. M., Gay, J. P., Feng, N., Battula, V. L., Kantarjian, H. M., Daver, N. G., et al. (2019) · Blood

Acute Myeloid Leukemia ResearchCancer, Hypoxia, and Metabolism

Cited by 19

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data

Jain, P., Kantarjian, H., Estey, E., Pierce, S., Cortes, J., Lopez-Berestein, G., & Ravandi, F. (2014) · Clinical Lymphoma Myeloma and Leukemia

Retinoids in leukemia and cellular processesAcute Myeloid Leukemia Research

Cited by 15

The many roads to universal health care in the USA

Jones, G., & Kantarjian, H. (2019) · The Lancet Oncology

Healthcare Policy and ManagementHealthcare Systems and Reforms

Cited by 13

Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research

Kantarjian, H., Zhai, Y., Oehler, V. G., Jamy, O., Koller, P. B., Haddad, F. G., Sasaki, K., & Jabbour, E. J. (2025) · Cancer

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 10

The presence of additional cytogenetic abnormalities ( ACAs ) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia

Haddad, F. G., Sasaki, K., Issa, G. C., Jabbour, E., & Kantarjian, H. (2024) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 4